ロード中...
Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2015-11-01
|
| シリーズ: | International Journal of Molecular Sciences |
| 主題: | |
| オンライン･アクセス: | http://www.mdpi.com/1422-0067/16/11/25950 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|